For most of his adult life, Aaron Presley, age 34, felt like a husk of a person, a piece of "garbage."
Exploring the companies and themes that make up this emerging and exciting new sector
Small Pharma Successfully Completes Phase I Clinical Trial Of DMT In Combination With Supportive Psychotherapy
Small Pharma shows DMT to be well-tolerated and safe for the study population as it moves forward toward a Phase IIa clinical trial.
Psyched Wellness Initiates a Clinical Sleep Study on Humans for a Structure/Function Claim For AME-1
Psyched Wellness is preparing for a clinical sleep study for its proprietary extract, AME-1.
New neuroscience research suggests the cerebral cortex acts as the brain’s hourglass
No one can stay awake forever. While we’re awake, our need for sleep gradually increases.
Study on MDMA for Traumatic Brain Injury Boosted By $1.5M Donation
Wesana Health committed to fund a MAPS study on MDMA for traumatic brain injury.
AdvisorShares Launches Psychedelics ETF (Ticker: PSIL)
AdvisorShares' new psychedelics ETF commences trading today on the NYSE Arca Exchange (symbol "PSIL") with a focus on small-cap psychedelic stocks.
The Two-Pronged Psychedelics Solution To The Opioid Crisis
Clinical research is rapidly advancing in using psychedelic drugs to treat opioid addiction. However, psychedelics can also reduce opioid-related deaths as a SUBSTITUTE for opioids.
California Activists Cleared To Collect Signatures For Psilocybin Legalization Ballot Initiative
California activists are now cleared to begin collecting signatures for an initiative to legalize psilocybin mushrooms in the state.
COMPASS Pathways acquires IP portfolio of novel psychedelic compounds and prodrugs
Compass Pathways acquires an unspecified IP portfolio of psychedelic and emphathogenic substances.
House Could Vote On Psychedelics Research For Military And Marijuana Banking As Part Of Defense Bill
House lawmakers have introduced a series of drug policy-related amendments to defense legislation, including proposals to facilitate research on the benefits of psychedelics for active duty military personnel and to protect banks that service state-legal marijuana businesses.
Perception Neuroscience initiates Phase 2a study of PCN-101 (R-ketamine) for treatment resistant depression
Atai affiliate, Perception Neuroscience is commencing a Phase 2a clinical trial of an R-ketamine medication for the treatment of depression.
Wesana Health Commits Funding of $1.5 Million To Support MAPS’ Research Pipeline
Wesana looks to expand its TBI-based psychedelics research into MDMA, with a new research partnership with MAPS.